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Abstract
Reactive arthritis (ReA) following bacterial infection from the urogenital and gastrointestinal tract is widely
described but is not typical post-viral infections. This report presents the second case of ReA after severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States. A 45-year-old black
male with chronic low back pain was hospitalized for 45 days with coronavirus disease 2019 (COVID-19),
complicated due to the development of multiorgan failure managed with intubation, extracorporeal
membrane oxygenation, and hemodialysis. He was subsequently discharged to an acute rehabilitation
facility where he complained of new-onset pain in his shoulders, left elbow, and left knee three weeks after a
negative SARS-CoV-2 test. He was readmitted from his acute rehabilitation facility due to recurrent fever
and the development of a swollen, warm left knee. Laboratory studies at readmission showed elevated
inflammatory markers, negative extensive infectious disease workup, and aseptic inflammatory left knee
synovial fluid without crystals. Testing returned negative for most common antibodies seen in immunemediated arthritides (e.g., rheumatoid arthritis, systemic lupus erythematosus), as well as for common
respiratory and gastrointestinal tract pathogens responsible for viral arthritis. The multidisciplinary
inpatient medical team deemed the clinical presentation and laboratory findings most consistent with ReA.
The patient received a course of oral corticosteroids, followed by a second course due to the recurrence of
symptoms weeks after initial treatment and recovery. The current body of medical literature on SARS-CoV-2
pathophysiology supports plausible mechanisms on how this infection may induce ReA. Such a scenario
should be considered in the differential of COVID-19-recovered patients presenting with polyarthritis as
prompt steroid treatment may help patient recovery.

Categories: Internal Medicine, Infectious Disease, Rheumatology
Keywords: reactive arthritis, polyarthritis, covid-19, sars-cov-2, case report

Introduction
Patients with reactive arthritis (ReA) typically present with aseptic oligoarthritis one to six weeks after
extra-articular infection, usually of gastrointestinal or urogenital origin [1]. Although less commonly
reported in the medical literature, the respiratory tract is also a site of underlying infection that can lead to
ReA. Only a few cases of ReA in the context of viral infections have been reported [2]. Since the beginning of
the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, epidemiologic data have
allowed scientists to build accurate clinical case definitions of coronavirus disease 2019 (COVID-19).
However, some questions remain partially unanswered when it comes to the post-infection evolution. We
present a case of ReA following SARS-CoV-2 infection, adding to the building literature detailing the postCOVID-19 manifestations.

Case Presentation
A 45-year-old black male with a family history of hypertension and prostate cancer, a personal history of
chronic low back pain status post spinal fusion, and a recent 45-day hospitalization for COVID-19
pneumonia developed a new-onset polyarthritis three days after his discharge to acute inpatient
rehabilitation. His COVID-19 syndrome consisted of a five-day history of productive cough and fever with a
real-time polymerase chain reaction (RT-PCR) of his nasal swab positive for SARS-CoV-2. After admission,
his COVID-19 pneumonia was managed with azithromycin, ceftriaxone, hydroxychloroquine, and
tocilizumab. He later developed multiorgan failure during his hospitalization, which required 21 days of
intubation with prone positioning, 16 days of veno-venous extracorporeal membrane oxygenation, and
continuous renal replacement therapy. He had two negative repeat testing for SARS-CoV-2 on days 27 and
31.
On day 48, while discharged to our rehabilitation hospital, he complained of significant pain in his
shoulders, left elbow, and left knee. He was readmitted on day 52, given worsening limiting pain and
recurrence of fever. At readmission, he was febrile to 101.1°F, tachycardic to 119 beats per minute, and
tachypneic to 23 beats per minute. He was noted to have an erythematous, warm, swollen left knee, as
shown in the X-ray (Figure 1). He did not have rash, conjunctivitis, or urethritis.
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FIGURE 1: X-ray of the left knee.
(A) Anteroposterior view. (B) Lateral view.

Pertinent readmission labs were notable for elevated lactate at 2.3 mmol/L, erythrocyte sedimentation rate
at 136 mm/hour, C-reactive protein at 178 mg/dL, and white blood cell (WBC) count at 17.5 × 103/uL. Repeat
cultures (blood and urine), transthoracic echocardiography, and lower extremity duplex were all negative.
Left knee arthrocentesis yielded 11 × 103/uL WBC with 94% polymorphonuclears, no microscopic evidence of
monosodium urate (MSU) and calcium pyrophosphate, and no microorganisms in the synovial fluid culture.
Antigenic tests for gonorrhea, chlamydia, hepatitis B, Clostridioides difficile, and HIV were negative.
Serologic tests for rheumatoid factor, anti-cyclic citrullinated peptide antibodies, cytomegalovirus, EpsteinBarr virus, enterovirus, parvovirus B19, and Treponema pallidum were negative. The multidisciplinary
medical team diagnosed the patient with ReA. Given his recent renal impairment, they started him on a
tapered dose of oral corticosteroid with significant improvement in pain and resolution of fever.

Discussion
Both the definition and the diagnosis of ReA have suffered from a lack of consensus among experts in the
medical community. Some authors reserve the term ReA for post-inflammatory arthritis caused by common
bacteria, while other forms of arthritis caused by other pathogens are referred to as post-infectious arthritis
[3]. In 1969, ReA was defined as aseptic arthritis following remote infection, usually from the urogenital or
gastrointestinal tract [4]. Per this more liberal definition, experts at the 1999 international workshop on ReA
in Germany offered a list of causative pathogens and tentative classification criteria [5]. Although there are
no clearly established criteria for the diagnosis or classification of ReA, the diagnosis is usually made using
clinical and microbiological findings [6].
Hypothetically, any microorganism can trigger the pathophysiology of ReA. In addition to the most
commonly encountered bacteria, there have been reports of fungal [7], parasitic [8], and viral [2] pathogens
in ReA. Since the beginning of the COVID-19 pandemic, few cases of SARS-CoV-2 ReA have been reported.
While caring for the patient presented, three additional cases were reported worldwide, including one in the
United States. The case we present here, the second in the United States, has unique features regarding the
preceding infection course, the outcomes, and therapeutic choices (Table 1) [9-11]. Indeed, our patient had a
more severe COVID-19 syndrome with more extended hospitalization and rapid deterioration with early
implementation of prolonged advanced supportive care. This might have played a role in the outcome of his
ReA, which was marked by a remission recurrence pattern despite using systemic steroids with a looming
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diagnosis of chronic ReA.

Country

COVID-19

Advanced supportive

Age/Gender

hospital stay

care

20 days

7-day intubation

Cases

Ono et al.

Japan

[9]

50/Male

Saricaoglu

Turkey

et al. [10]

73/Male

Danssaert

United States

et al. [11]

37/Female

Oligoarthritis (bilateral ankles) and enthesitis (right Achilles

NSAIDs, intraarticular

tendon)

corticosteroids

Clinical course

Moderate improvement

No

NSAIDs

Resolved

Diclofenac gel, gabapentin,

Enthesitis persisted for the next 4 weeks

and hydromorphone

managed with splinting, OT, and tramadol

interphalangeal of the second toe on the right foot

0 day

United States

No

Monoarthritis (hand), tendonitis (flexor and extensor hand)

21-day intubation, 16-day
45 days

45/Male

ReA treatment

Polyarthritis: Left MTP of the hallux, proximal, and distal
22 days

This case

ReA clinical presentation

Recurrence of polyarthritis managed with second
Polyarthritis (knee, elbows, shoulder)

Oral prednisone

ECMO, and dialysis

dose taper of steroid + PT/OT

TABLE 1: Reported cases of ReA following SARS-CoV-2 infection.
MTP: metatarsophalangeal; NSAIDs: non-steroidal anti-inflammatory drugs; PT/OT: physical therapy/occupational therapy; ECMO: extracorporeal
membrane oxygenation; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; ReA: reactive arthritis

Our patient presented with acute polyarthritis three weeks after a negative RT-PCR test for SARS-CoV-2. His
symptomatology was deemed less likely originating from other potential causes in the differential after
thorough diagnostic and etiologic workup. Although there was bacteremia during hospitalization, a negative
extensive infectious disease workup ruled out septic arthritis. Furthermore, Gram staining, PCR, and culture
of synovial fluid did not yield any microorganisms. Titration of the most common antibodies in immunemediated arthritides and PCR for common respiratory and gastrointestinal tract pathogens responsible for
viral arthritis yielded unremarkable results. Although our patient had an isolated episode of crystalline
negative podagra 12 years ago, the current knee arthrocentesis did not reveal MSU crystals, and his plasma
uric acid was normal. Despite chondrocalcinosis on knee radiography, there was no evidence of calcium
pyrophosphate crystals in synovial fluid. We ruled out viral arthritis from other common viral pathogens,
but we still cannot omit the possibility of SARS-CoV-2-induced arthritis. However, given the timeline of
occurrence, it seems less likely. Indeed, cases of delayed onset and prolonged arthritis in viral infections
have been frequently reported with alphaviruses and hepatitis C virus, none have been reported for
coronaviruses [12]. Studies show that typical musculoskeletal symptoms associated with SARS-CoV-2 tend
to present with acute myalgia and arthralgia rather than delayed clinical arthritis [13].
The interplay between host antimicrobial factors with the theory of unbalanced Th1/Th2 cytokine secretion
and genetic factors with the human leukocyte antigen (HLA) B27 theory in the pathophysiology of ReA [14]
may explain how the SARS-CoV-2 virus elicits ReA. Indeed, microorganisms in ReA are thought to trigger an
inflammatory response from the host through antigenic cross-reactivity [15]. Molecular mimicry is the
mechanism through which it occurs and has been well documented for bacterial pathogens commonly seen
in ReA [15]. Although not clearly understood, studies have shown that the pathogenesis of viral-induced
arthritis involves some degree of molecular mimicry, bystander activation, and viral persistence, depending
on the virus [16]. Moreover, viral-induced immunoreactivity plays a role in the pathogenesis of rheumatic
and autoimmune diseases parallel to other host-specific factors such as genetic susceptibility [17].
Therefore, the SARS-CoV-2 virus can elicit ReA.
Another potential mechanism of SARS-CoV-2-induced ReA includes the interaction of the virus with its
angiotensin-converting enzyme 2 (ACE2) receptors in the gastrointestinal tract. Studies have shown that
such an interaction downregulates ACE2 expression, limiting its functions [18] in gut immune and microbial
homeostasis [19]. In genetically susceptible individuals, it is suggested that such dysregulation of the gut
microbiome plays a role in the pathogenesis of spondyloarthropathies such as ReA [20]. Besides the
misfolding and the arthritogenic postulates [14], dysbiosis [20] is another hypothesis on the role of HLA B27
in ReA. Underlying the latter theory is the body of research on the regulatory functions of enterocytes ACE2
receptors. Despite the plausibility of this theory, more studies are needed to understand how this mechanism
may elicit ReA and the timeframe required to do so.
The body of literature on the manifestations following COVID-19 is expanding and has ramifications in
many disciplines. The medical community is still grasping the full picture of the aftermath of SARS-CoV-2
infection among recovered patients. Awareness about the possibilities of ReA in the immediate course of
recovery from COVID-19 is essential as it may impede physical and occupational therapies (PT/OT), which
are crucial in the recovery process. Moreover, in patients who have had a severe COVID-19 course and
required intensive care management, ReA may coexist with the active or lingering symptoms of critical
illness myopathy to further limit optimal gain from PT/OT. It points to the importance of an adequate
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multidisciplinary team involving rheumatologists, physiatrists, pain physicians, and PT/OT for efficient
management in such scenarios. Although seldom involved in the management, the expertise of
physiatrists/pain specialists can make a significant contribution. For instance, when anti-inflammatories are
contraindicated, or there is persisting recurrent pain despite standard of care, the use of multimodal pain
management is an available alternative. Among the cases reported, including this one, individuals benefited
from physiatrist care in only two instances.

Conclusions
This case raises awareness of the potential post-inflammatory manifestations that can plague the recovery
following COVID-19 infection. It adds to the growing literature emphasizing the need for clinicians to
consider ReA in arthritic presentations after COVID-19. On the other hand, it sheds light on the need for
more research to assess the alleged role of viral etiologies as potential pathogens in the occurrence of ReA.
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